Home » Topics » BioWorld Science

BioWorld Science
RSS

FDA approves expanded label for Keytruda for first-line treatment of metastatic non-squamous NSCLC

Aug. 21, 2018

Phase II trial of TLC-599 for osteoarthritis pain meets primary and key secondary endpoints

Aug. 21, 2018

Japanese approval for Tagrisso as first-line treatment of EGFR-mutated NSCLC

Aug. 21, 2018

New Rho kinase inhibitors described by Chiesi Farmaceutici

Aug. 21, 2018

Hanmi Science patents oncolytic compounds

Aug. 21, 2018

Vectura completes pediatric studies with VR-647 for asthma

Aug. 21, 2018

Antiangiogenic compounds synthesized at Celgene

Aug. 21, 2018

Adare Pharmaceuticals describes cysteamine prodrugs

Aug. 21, 2018

Biogen identifies new NRF2 activators

Aug. 21, 2018

Phase III study of MC2-01 cream in psoriasis vulgaris meets primary and secondary endpoints

Aug. 21, 2018

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for July 17, 2026.
ALN-5288 lowers tau levels in preclinical models
BioWorld Science
Pathological tau accumulation is a key driver of neurodegeneration in Alzheimer’s disease (AD) and other tauopathies such as progressive supranuclear palsy....
Dual FAAH/MAGL inhibition targets Alzheimer’s disease hyperexcitability
BioWorld Science
Reduced endocannabinoid signaling has been linked to neuronal hyperexcitability in Alzheimer’s disease (AD), suggesting that dual inhibition of fatty acid amide...
Capital remains selective in ‘barbell’ biotech market
BioWorld
Signs of recovery are emerging in the biotechnology investment sector, although investors across Asia say that capital is flowing selectively to companies that...
PSB-229 reduces plaque burden in Alzheimer’s models
BioWorld Science
Pyroglutamate-modified amyloid-β (pE3-Aβ) is a highly pathogenic Aβ species that accumulates within amyloid plaques and contributes to aggregation,...